R. Molife

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

David Olmos, Hendrik‐Tobias Arkenau, Joo Ern Ang et al. · Annals of Oncology · 2008 · 248 citations · Full text

Medicine, Oncology, Urology +17

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Debashis Sarker, R. Molife, T. R. J. Evans et al. · Clinical Cancer Research · 2008 · 137 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Yohann Loriot, Karim Fizazi, Robert J. Jones et al. · Investigational New Drugs · 2014 · 62 citations

Medicine, Oncology, Urology +17

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Nicola Steele, Jane A. Plumb, Laura Vidal et al. · Cancer Chemotherapy and Pharmacology · 2010 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Alastair Greystoke, Sarah P. Blagden, Anne Thomas et al. · Annals of Oncology · 2006 · 24 citations · Full text

Medicine, Oncology, Pharmacokinetics +13